Next-generation SmartRobotics system advances JMC’s leadership in orthopedic innovation

July 13, 2026Jupiter Medical Center (JMC) is proud to announce that it is the first hospital in the world to offer robotic shoulder replacement using the Mako 4.0 SmartRobotics™ system. The milestone builds on JMC’s introduction of robotic shoulder replacement in the fall of 2025 and further positions the independent, not-for-profit hospital as a global leader in orthopedic robotic-arm assisted surgery.

Mako 4.0 is the latest update to the Mako system and includes all the same benefits available with the current platform, including AccuStop™ technology, and CT-based intraoperative planning and guidance. The updated system includes improved visualization and tracking, along with several advanced features, such as virtual screw-depth measurement. The new features are designed to further enhance the precision and efficiency of robotic-assisted shoulder arthroplasty.

“Being the first in the world to offer the Mako 4.0 robotic shoulder replacement is a meaningful achievement,” said Amit Rastogi, MD, MHCM, President and CEO of Jupiter Medical Center. “It reflects Jupiter Medical Center’s commitment to leading the future of orthopedic care. By investing in the most advanced surgical technologies and collaborating with outstanding physicians, we are expanding possibilities for patients, including providing greater precision, a more personalized surgical experience, and the highest standard of care close to home.”

Brian W. Hill, MD, a fellowship-trained and board-certified orthopedic surgeon specializing in complex shoulder conditions, was the first surgeon at JMC to perform shoulder replacement using the new system.

“To be the first surgeon in the world to use the Mako 4.0 system for robotic shoulder replacement is an extraordinary honor,” said Dr. Hill. “As a surgeon, my focus is always on giving patients the best possible outcome, and this technology represents an important step forward in the precision and personalization we can bring to shoulder replacement surgery. I am grateful to Jupiter Medical Center for its continued leadership, vision, and commitment to bringing the most advanced orthopedic innovations to our patients and our community.”

Jupiter Medical Center is one of Florida’s top-rated hospital systems for orthopedic care. In 2025, JMC was recognized by Healthgrades as America’s 100 Best Hospitals for Joint Replacement, and it holds the Joint Commission Gold Seal of Approval for Total Hip & Knee Replacement, Total Shoulder Replacement, and Spine Surgery. More recently, Money Magazine recognized it as one of the Best Hospitals nationwide for orthopedic surgery.

Additionally, these clinical achievements are supported by significant investments in facilities, including the recent opening of Jupiter Medical Center’s new Tim and Jayne Donahue Patient Care Tower, which features two dedicated orthopedic floors, each with its own rehabilitation gym, all designed to enhance surgical recovery, patient comfort, and care efficiency.

Patients who may benefit from shoulder replacement include those with severe arthritis, irreparable rotator cuff tears, or persistent pain that limits daily activities or sleep. Patients and referring providers can contact Jupiter Medical Center’s Orthopedic Navigator at 561-263-3633 for information about shoulder replacement options, including Mako SmartRobotics™.

For more information about Jupiter Medical Center, visit jupitermed.com, call (561) 263-2234, or follow Jupiter Medical Center on Facebook and Instagram @jupitermedicalcenter or on ‘X’ @JupiterMedCtr.

ABOUT JUPITER MEDICAL CENTER 
Rated #1 in the region for quality, safety and patient experience, Jupiter Medical Center is the leading destination for world-class health care in Palm Beach County and across the Treasure Coast. Jupiter Medical Center’s state-of-the-art facilities and leading-edge technologies enable its award-winning physicians to provide a comprehensive continuum of inpatient and outpatient health care services. Jupiter Medical Center’s specialty centers of excellence include: comprehensive cancer care, cardiovascular care, orthopedics, neurosciences, and women’s and children’s services. For more information about Jupiter Medical Center, please call 561-263-2234 or visit www.jupitermed.com.




Revises 2026 Guidance

HCA Healthcare, Inc. (NYSE: HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preliminary financial and operating results are subject to finalization of the Company’s quarterly financial and accounting procedures.

HCA anticipates revenues in the second quarter of 2026 to approximate $20.230 billion, compared to $18.605 billion in the second quarter of 2025. Net income attributable to HCA Healthcare, Inc. is expected to approximate $1.699 billion, or $7.62 per diluted share, compared to $1.653 billion, or $6.83 per diluted share, in the second quarter of 2025. Results for the second quarter of 2026 include anticipated gains on sales of facilities of $10 million, or $0.03 per diluted share. Results for the second quarter of 2025 included losses on sales of facilities of $3 million, or $0.01 per diluted share.

For the second quarter of 2026, Adjusted EBITDA is expected to approximate $4.027 billion, compared to $3.849 billion in the second quarter of 2025. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions increased 2.5 percent and same facility equivalent admissions increased 2.7 percent in the second quarter of 2026 compared to the prior year period. Same facility emergency room visits increased 3.6 percent in the second quarter of 2026 compared to the prior year period. Same facility inpatient surgeries declined 2.3 percent, and same facility outpatient surgeries declined 3.4 percent in the second quarter of 2026 compared to the same period of 2025.

“Our colleagues continue to manage well through the positive and negative factors that have impacted our business in the first half of the year, and I want to thank them for their great work. As we look to the balance of the year, we have adjusted our guidance to reflect these factors. Moreover, we remain confident in our ability to navigate through this dynamic environment, maintain our focus and investments on improving patient care, and execute on our strategic plan to digitize and grow our healthcare networks,” said Sam Hazen, Chief Executive Officer of HCA Healthcare.

Second Quarter Commentary

During the second quarter, the Company experienced a payer mix shift driven by an increase in uninsured volume, primarily due to patients who lost coverage on the health insurance exchanges. The Company estimates this payer mix shift had an unfavorable impact on income before income taxes of approximately $400 million during the second quarter. This amount includes an increase of approximately $75 million related to the Company’s previous estimate of the first quarter health insurance exchange impact. In addition, to a lesser degree the Company experienced a service mix shift primarily related to a decline in surgical volume.

The Company also experienced positive factors including growth in admissions, equivalent admissions and ER visits, increased benefit from Medicaid Supplemental Payment Programs and improved expense trends. During the second quarter, the Company recognized approximately $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, primarily related to the state of Florida for the time period October 1, 2024 through June 30, 2026, to reflect the impact of the state directed payment program approved during the quarter by the Centers for Medicare and Medicaid Services.

The Company will provide additional commentary on its second quarter earnings call.

2026 Updated Guidance and Key Assumptions

Based on results through the first half of the year, the Company has revised its 2026 guidance as follows:

Previous 2026 Guidance
Ranges, as of January 27, 2026

Revised 2026 Guidance
Ranges, as of July 14, 2026

Revenues

$76.500 to $80.000 billion

$77.000 to $79.500 billion

Net Income Attributable to HCA Healthcare, Inc.

$6.495 to $7.035 billion

$6.300 to $6.700 billion

Adjusted EBITDA

$15.550 to $16.450 billion

$15.400 to $16.100 billion

EPS (diluted)

$29.10 to $31.50 per diluted share

$28.70 to $30.50 per diluted share

The Company revised its 2026 key assumptions related to the unfavorable impact on income before income taxes from payer mix shifts due to the health insurance exchanges, as well as the incremental net benefit from Medicaid Supplemental Payment Programs, as follows:

Previous 2026 Estimates, as of April 24, 2026

Revised 2026 Estimates, as of July 14, 2026

Health Insurance Exchanges

($600) to ($900) million

($1.000) to ($1.200) billion

Medicaid Supplemental Payment Programs

($50) to ($250) million

$300 to $500 million

The Company’s 2026 estimate for capital expenditures of $5.0 billion to $5.5 billion, excluding acquisitions, remains unchanged.

The Company’s guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding volume growth coupled with an anticipated mostly stable operating environment, payer mix, service mix, the impact of current and future health care public policy developments, including the estimated impact on health insurance exchanges from administrative reforms and the expiration of the enhanced premium tax credits, anticipated results from resiliency initiatives, as well as general business or economic conditions, including inflation and the impact of trade policies, including tariffs, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets. In addition, the Company’s guidance excludes the impact of future approvals that could impact reimbursement under certain state Medicaid directed and supplemental payments.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The preliminary financial information set forth above has been prepared by management based upon information available to it as of the date hereof and has not been reviewed or audited by the Company’s independent registered public accounting firm. These preliminary results are subject to the completion of the Company’s customary quarterly financial and accounting procedures. There can be no assurance that the Company’s actual results for the quarter ended June 30, 2026 will not differ materially from the preliminary estimates set forth herein. These differences could be material and adverse and may be the result of the finalization of the Company’s financial close procedures, final adjustments and other developments. Accordingly, you should not place undue reliance on these preliminary estimates. The Company does not undertake any obligation to update or supplement the preliminary estimates set forth herein, whether as a result of new information, subsequent events or otherwise, except as may be required by law.

The Company’s updated guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Second Quarter 2026 Earnings Conference Call

HCA Healthcare will host its second quarter earnings call on Friday, July 24, 2026, at 9:00 a.m. Central Time. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast will also be available on a replay basis beginning that afternoon. The webcast can be accessed through the Company’s Investor Relations web page at: https://investor.hcahealthcare.com/events-and-presentations/default.aspx

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s expected results for the second quarter of 2026, the Company’s financial guidance for the year ending December 31, 2026, as well as other statements that do not relate solely to historical or current facts, and are subject to finalization of the Company’s second quarter financial and accounting procedures. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic or business conditions nationally and regionally in our markets, including inflation, and the impact of trade policies, including changes in, or the imposition of, tariffs and/or trade barriers; changes in revenues resulting from declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, pharmaceuticals, supply chain or other expenditures; workforce disruptions; supply and pharmaceutical shortages and disruptions (including as a result of tariffs or geopolitical disruptions); and the impact of federal government shutdowns, holds on or cancellations of congressionally authorized spending and interruptions in the distribution of governmental funds, (2) the impact of current and future health care public policy developments and the implementation of new, and possible changes to existing, federal, state or local laws and regulations affecting health care spending or the health care industry, including the expiration at the end of 2025 of enhanced premium tax credits (“EPTCs”) for eligible individuals purchasing insurance coverage through federal and state-based health insurance marketplaces, changes in the structure and administration of, and funding for, federal and state agencies and programs, effects of the 2025 Federal Budget Act (the “FBA”) and efforts to address health care affordability, (3) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions, and the potential for future deficit or other spending reduction legislation that may alter current spending reductions, which include cuts to Medicare payments, or impose additional spending reductions, (5) the ability to achieve operating and financial targets, develop and execute resiliency plans to offset to the extent possible impacts from the FBA, the expiration of EPTCs and tariffs, attain expected levels of patient volumes and revenues and service mix, and control the costs of providing services, (6) possible reductions or other changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs, Medicaid waiver programs and state directed payment arrangements, any of which may negatively impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (7) the results of our efforts to use technology and resilience initiatives, including artificial intelligence and machine learning, to drive efficiencies, better outcomes and an enhanced patient experience, (8) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (9) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (10) the highly competitive nature of the health care business, (11) changes in service mix, revenue mix and service volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (12) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (13) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (14) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (15) changes in accounting practices, (16) the emergence of and effects related to pandemics, epidemics and outbreaks of infectious diseases or other public health crises, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving or failure to receive payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of actual and potential cybersecurity incidents or security breaches involving us or our vendors and other third parties, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, including Hurricanes Milton and Helene, physical risks from changing global weather patterns or similar events beyond our control on our assets and activities and the communities we serve, (25) changes in U.S. federal, state, or foreign tax laws, interpretations of tax laws by taxing authorities, other standard setting bodies or judicial decisions, (26) changes to, and the timing and amount of future approvals (if any) of, state Medicaid directed and supplemental payments and (27) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2025 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

Preliminary Operating Results Summary

(Dollars in millions, except per share amounts)

Second Quarter

2026

2025

Revenues

$

20,230

$

18,605

Net income attributable to HCA Healthcare, Inc.

$

1,699

$

1,653

Losses (gains) on sales of facilities (net of tax)

(8

)

3

Net income attributable to HCA Healthcare, Inc.,
as adjusted (a)

1,691

1,656

Depreciation and amortization

944

863

Interest expense

599

568

Provision for income taxes

562

524

Net income attributable to noncontrolling interests

231

238

Adjusted EBITDA (a)

$

4,027

$

3,849

Adjusted EBITDA margin (a)

19.9

%

20.7

%

Diluted earnings per share:

Net income attributable to HCA Healthcare, Inc.

$

7.62

$

6.83

Losses (gains) on sales of facilities

(0.03

)

0.01

Net income attributable to HCA Healthcare, Inc.,
as adjusted (a)

$

7.59

$

6.84

Shares used in computing diluted earnings per
share (millions)

222.828

241.911

___________________

(a)

Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). These non-GAAP financial measures are adjusted to exclude losses (gains) on sales of facilities and losses on retirement of debt. We believe net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that adjustments, including losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

Net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., as adjusted, diluted earnings per share, as adjusted, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

2026 Operating Results Forecast

(Dollars in millions, except per share amounts)

For the Year Ending

December 31, 2026

Low

High

Revenues

$

77,000

$

79,500

Net income attributable to HCA Healthcare, Inc. (a)

$

6,300

$

6,700

Depreciation and amortization

3,745

3,795

Interest expense

2,410

2,470

Provision for income taxes

1,975

2,125

Net income attributable to noncontrolling interests

970

1,010

Adjusted EBITDA (a) (b)

$

15,400

$

16,100

Diluted earnings per share:

Net income attributable to HCA Healthcare, Inc.

$

28.70

$

30.50

Shares used in computing diluted earnings per share (millions)

219.500

219.500

The Company’s forecasted guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.

___________________

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (“GAAP”). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our healthcare facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.




July 13, 2026 — Suncoast Credit Union Foundation has granted Lee Health more than $25,000 to support the in-hospital schoolteacher at Golisano Children’s Hospital. The gift helps ensure pediatric patients continue their education while receiving medical care. The in-hospital schoolteacher works closely with students, families and home schools to minimize academic disruption and provide a sense of routine during treatment and recovery. Additionally, funds provide essential classroom resources for learning during hospitalizations.

“We are deeply grateful for Suncoast Credit Union Foundation’s continued generosity and commitment to our patients and families,” said Michele King, director of child advocacy at Golisano Children’s Hospital. “This support helps children maintain academic progress and important connections to their school communities, creating a sense of normalcy while they focus on healing.”

Suncoast Credit Union, Florida’s largest credit union, founded the Suncoast Credit Union Foundation to promote the education, health and emotional well-being of children in the communities it serves. Each time a Suncoast member uses a debit or credit card, the credit union donates two cents to the Foundation to support local initiatives. Since its inception in 1990, the Foundation has raised and donated millions of dollars to programs that positively impact children and families throughout Florida.

“Suncoast Credit Union is proud to help provide an in-hospital teacher at Golisano Children’s Hospital,” said Jeff Kunberger, executive director of Suncoast Credit Union Foundation. “Continuing education is important, and this donation helps ensure young patients can continue learning during their hospital stay.”

Services like the in-hospital schoolteacher are part of the Golisano Children’s Hospital mission to treat every child with care and compassion. To learn more about making an impact through Golisano Children’s Hospital, visit GiveGolisano.org.

About Lee Health Foundation

Lee Health Foundation raises philanthropic support on behalf of community-focused nonprofit Lee Health to establish, expand, and enhance lifesaving and preventive programs in Southwest Florida. Contributions to the Foundation benefit all five Lee Health hospitals and specialty services. In the past year, the Foundation provided $34+ million in funding to enhance patient care throughout the region. Please visit LeeHealthFoundation.org for more information about the role of Lee Health philanthropy in Southwest Florida.

About Suncoast Credit Union

Suncoast Credit Union is the largest credit union in Florida, the seventh largest in the United States by membership and the 10th largest by assets, with $21.1 billion. Chartered in 1934 as Hillsborough County Teachers Credit Union, Suncoast operates 80 full-service branches and serves more than 1.4 million members statewide. As a community credit union, anyone who lives, works or attends school in Suncoast’s service area is eligible for membership. In 2021, Suncoast’s field of membership was expanded to include public K-12 teachers, college educators, and educational support staff across all of Florida’s 67 counties. Suncoast is dedicated to supporting the communities it serves, guided by its “people helping people” philosophy. Since 1990, the Suncoast Credit Union Foundation has raised and donated more than $63 million to organizations and initiatives that support the health, education and emotional well-being of children.  For more information, visit suncoast.com or follow us on social media: Facebook, LinkedIn, Twitter and Instagram.




Dr. Rosenblatt is now treating South Florida patients who have urinary and fecal incontinence, pelvic organ prolapse, overactive bladder and more. 

July 13, 2026 – South Florida urogynecologist Peter Rosenblatt, MD has joined Holy Cross Medical Group, a multi-specialty physician-employed group of more than 180 physicians providing services throughout Broward County. He brings 35 years of subspecialty experience in treating pelvic floor prolapse, overactive bladder and incontinence issues, common conditions that are often a source of embarrassment and cause women to suffer in silence.

 

Pelvic organ prolapse occurs when the muscles and tissues that support the uterus, bladder and rectum weaken or loosen, and gravity causes the organs to drop. Women are frequently diagnosed as a result of vaginal childbirth; long-term pressure on the abdomen due to obesity, chronic coughing or strenuous bowel movements; aging; and family history. Research has also indicated that the condition is especially prevalent among athletes. Although women of any age can experience pelvic organ prolapse, it is more common during peri or post-menopause than in younger women.

 

“My goal is to make our patients feel comfortable sharing their concerns and become part of the decision-making process since there are often many different solutions to pelvic floor disorders,” Dr. Rosenblatt assured. “I am excited to work in the same community in which I now live and provide high-quality care for women in the area. I can already feel the commitment of the staff to providing care for patients of all denominations and for those who are underprivileged or disadvantaged.”

 

Dr. Rosenblatt is an expert in performing laparoscopic reconstructive surgery for pelvic organ prolapse and minimally invasive surgery for urinary and fecal incontinence. He has also developed innovative surgeries for fecal incontinence using a mesh sling and pelvic organ prolapse without the need for hysterectomy. Additional conditions he treats are overactive bladder, genitourinary fistulas and recurrent urinary tract infections (UTIs). 

 

In addition to practicing medicine, Dr. Rosenblatt has pioneered new technology and taught fellows, residents and medical students at prestigious institutions including Brown University School of Medicine and Harvard Medical School.

 

“One of the last taboo subjects that women find it difficult to discuss with their health care providers is accidental bowel leakage, also known as fecal incontinence,” he explained. “This condition affects literally millions of women and there have been limited options for treating women until relatively recently. Although many women may be effectively managed conservatively, I developed a minimally invasive surgical procedure called TOPAS that has been shown to be very effective.” 

 

Dr. Rosenblatt graduated from Brown University with a Bachelor of Arts in biopsychology and earned his medical degree from Tufts University School of Medicine. He completed an internship and residency in obstetrics and gynecology at University of Massachusetts Medical School, as well as a fellowship in urogynecology and pelvic reconstructive surgery at Brown University School of Medicine, Women & Infants’ Hospital. He was drawn to specialize in this field during his training because he discovered pelvic floor disorders are underreported by women and underrecognized by clinicians, and he wanted to provide the solution.

 

“There’s a large demand for urogynecology services in our community. The addition of another skilled urogynecologist ensures that women have access to the much-needed care they deserve. Dr. Rosenblatt’s surgical training and outcomes are outstanding. He conveys confidence yet is humble. His approach is calming and reassuring,” said Kimberley Graham, Service Line Director at Holy Cross Medical Group. “Urogynecologists combine the expertise of a urologist and gynecologist. The volume of women in our demographic area that need his services and expertise will organically grow and elevate the image and quality of our Women’s Service Line.”

 

Dr. Rosenblatt previously worked at Mount Auburn Hospital, Beth Israel-Deaconess Medical Center, Newton-Wellesley Hospital and New England Medical Center in Massachusetts, as well as Catholic Medical Center in New Hampshire. An innovator and industry leader, Dr. Rosenblatt has written research papers and is a sought-after speaker regionally, nationally and internationally. He has served on the Board of Directors for both the American Urogynecologic Society (AUGS) and the Society of Gynecologic Surgeons (SGS) and was President of SGS from 2019 to 2020. 

 

Patients may visit Dr. Rosenblatt at the Urogynecology & Reconstructive Pelvic Surgery office within the Holy Cross Medical Group – Women’s Center, located at 1000 NE 56th Street in Fort Lauderdale. He will also be seeing patients at the new Holy Cross Health Center, located at 340 S. Federal Highway in Deerfield Beach. To schedule an appointment, please call 954-229-8660 for Fort Lauderdale, 954-542-0001 for Deerfield Beach or visit holy-cross.com.

 

ABOUT HOLY CROSS HEALTH

A member of Trinity Health, Fort Lauderdale-based Holy Cross Hospital, dba Holy Cross Health, is a full-service, not-for-profit, Catholic, teaching hospital operating in the spirit of the Sisters of Mercy. Holy Cross has been recognized for six Types of Care in U.S. News and World Report’s 2025-2026 Best Hospital rankings, was named among the 2024 America’s Best-In-State Hospitals by Newsweek and selected as a Forbes America’s Best Employers for Healthcare Professionals in 2025. Holy Cross has also been designated as a 2025 High Performer by the Human Rights Campaign Foundation for LGBTQ+ health care access and Holy Cross Health Foundation is designated as a High Performer from the Association for Healthcare Philanthropy. Through strategic collaborations and a commitment to being a person-centered, transforming, healing presence, the 557-bed hospital offers progressive inpatient, outpatient and community outreach services and clinical research trials to serve as the community’s trusted health partner for life. Holy Cross Health also includes Holy Cross HealthPlex outpatient facility, urgent care centers and more than 40 Holy Cross Medical Group physician practices. To learn more about Holy Cross Health, visit holy-cross.com. Connect with Holy Cross Health on Facebook, LinkedIn and Instagram.

 




The Weinbach Group Lands A Massive Haul At National Competition And Captured ‘Best Of Show’ For Its Digital Healthcare Advertising Work

JULY 13, 2026 The Weinbach Group celebrated a landmark achievement at the 43rd Annual Healthcare Advertising Awards, taking home more awards than any Florida ad agency. In total, the healthcare marketing firm won 15 prizes, including 6 gold awards, the most in the State. Its success at the nation’s largest medical advertising competition placed The Weinbach Group among the top five winningest marketing companies in the entire Southeastern United States. What’s more, the Miami healthcare advertising agency won the competition’s highest honor, Best of Show, for an online ad it created for a chain of dermatology clinics, Florida Dermatology Specialists.

The Healthcare Advertising Awards, sponsored by Healthcare Marketing Report, is the nation’s premier competition for healthcare advertising agencies as well as in-house marketing teams at hospitals and health systems. This year’s contest attracted more than 4,300 entries, making The Weinbach Group’s wins particularly noteworthy. A national panel of judges reviewed all 4,000-plus entries based on creativity, quality, message effectiveness, audience appeal, graphic design, and overall impact. The judges recognized only 21 contestants, including The Weinbach Group, with the Best of Show designation for their overall excellence and breakthrough advertising.

“Clients choose our agency because of our deep understanding of the healthcare industry and our ability to craft effective marketing campaigns on their behalf,” said Daniel Weinbach, president and CEO of The Weinbach Group. “This year’s wins demonstrate their trust in us is well deserved. I think it’s fair to say, our performance at The Healthcare Advertising Awards cements our status as true healthcare marketing experts and differentiates our agency amid this crowded and competitive field.”

In addition to its Best of Show win for Florida Dermatology Specialists, the Weinbach Group won awards for healthcare marketing projects it produced on behalf of other clients, including Mount Sinai Medical Center, Genuine Health Group, and Advocate Radiation Oncology. For many of these clients, the veteran agency’s work targeted physician audiences. In fact, the healthcare marketing agency was the only marketing company in Florida to capture awards specifically in categories for provider-facing communication, winning both Gold and Bronze awards in the Physician Referral category for Advocate Radiation Oncology.

The Miami-based marketing firm also racked up wins for its digital projects, including in the website development category and multiple wins in the digital video ad category.

The Weinbach Group, which was founded in 1987 as a Miami public relations firm, has grown into a fully integrated marketing communications agency. Over the past several decades, it has earned national acclaim for its healthcare marketing specialization. Last year, the agency was named a “Marketing Team of the Year” finalist by the American Marketing Association, and it maintains a five-star rating on Clutch for its outstanding work.

To see all of The Weinbach Group’s winning projects from this year’s Healthcare Advertising Awards, click here: https://www.weinbachgroup.com/healthcare-advertising-awards.

About The Weinbach Group

The Weinbach Group, now in its fourth decade of business, consistently ranks among South Florida’s top advertising, public relations, and marketing firms. The agency serves clients in a range of industries and is best known as a healthcare marketing firm. Notable clients have included Mount Sinai Medical Center, ChenMed Senior Care, The Renfrew Center for Eating Disorders, HCA, University of Miami Miller School of Medicine, and Jackson Health System.